Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.

Pavel KlenerDavid SalekRobert PytlikHeidi MocikovaKristina ForsterovaPetra BlahovcovaVit CamprVit ProchazkaAles ObrRadek JaksaJana KuntscherovaLudmila BoudováRoman KodetAndrea JanikovaMarek Trneny

Published in: American journal of hematology (2018)

Keyphrases

stem cell transplantation
free survival
newly diagnosed
high dose
diffuse large b cell lymphoma
randomized controlled trial
bone marrow
cell therapy
chronic lymphocytic leukemia
platelet rich plasma
hodgkin lymphoma
low dose